Global Direct to Consumer Microbiome Analyzing Market Expected to Grow At a CAGR of 11.8% During the Forecast Period

The latest market report published by Credence Research, Inc. “Direct to Consumer Microbiome Analyzing Market : Growth, Future Prospects, and Competitive Analysis, 2019 – 2027” the direct to consumer microbiome analyzing market expected to grow at a CAGR of 11.8% during the forecast period from 2019 to 2027.

Market Insights

The global direct to consumer microbiome analyzing market is growing effectively from 2019 to 2027 accredited to the rise in interest for gut microbiome testing kits along with improved technology expansion on a global scale. The microbiome analyzing test kits provide a detailed profile and actionable advice on an individual’s health, nutrition and physical activity. Top companies are differentiating its consumer gut bacteria tests into actionable diagnostics. The personalized health technology companies in the U.S. and U.K are gaining traction in the genomics marketplace, and additionally, they educate their consumers on the big data line to their personal care. Moreover, increasing incidences of genetic disorders along with wide applications of direct to consumer microbiome analyzing in primary detection of oncology, chronic diseases, infections and other genetic disorders will drive the growth of the market during the forecast period.

Top manufacturers are mainly focusing on new product expansion and FDA approval. The increasing number of partnerships with academic research centers and alliance by key laboratories internationally will drive the growth of the market in the near future. For instance, in June 2019, Atlas Biomed Group Limited (personalized health technology company), expanded its offerings for DNA and Microbiome test in Canada, succeeding solid success in the European market. Nevertheless, less awareness related to the pipeline products in the DNA testing industry and less favorable outcomes along with fewer treatment options are few factors restraining the overall growth of the direct to consumer microbiome analyzing market on a global scale. Additionally, the U.S. FDA has now placed regulations for pre-market assessment in case of DNA-based genetic test kits.

Key Market Movements:

  • Globally, the direct to consumer microbiome analyzing is growing at a CAGR of 11.8% for the period from 2019 to 2027
  • The Europe market will gain traction due to its improved infrastructure, large patient pool and new technology expansion
  • Launch of SmartGut and Viome Gut Intelligence™ Test will further spur revenue growth during the forecast period
  • Growing number of partnerships, strong pipeline products for direct to consumer microbiome analyzing, and increased personal care expenditure in the developing nations will drive the overall market growth
  • Major players in this vertical are uBiome, Inc., Viome, Inc., Atlas Biomed and others

Browse full report at

The Global Direct to Consumer Microbiome Analyzing Market is Segmented into:

Research Period 2017-2027
Base Year2018
Forecast Period 2019-2027
Historical Year 2017
Unit USD Million
Segmentation By Product Type (2017–2027; US$ Mn)
 By Application Segment (2017–2027; US$ Mn)
 By Geography Segment (2017–2027; US$ Mn)

*Complete segmentation list is on report page